Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
GRIN2C Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GRIN2C Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of GRIN2C sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GRIN2A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GRIN2A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of GRIN2A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGFN1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGFN1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGFN1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GRIN2B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GRIN2B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of GRIN2B sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
DCC Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
DCC Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of DCC sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EEA1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EEA1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of EEA1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
VSIG8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
VSIG8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of VSIG8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
WFIKKN1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
WFIKKN1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of WFIKKN1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
WFIKKN2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
WFIKKN2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of WFIKKN2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
VSIG10L Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
VSIG10L Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of VSIG10L sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
VSIG10 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
VSIG10 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of VSIG10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
VSIG4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
VSIG4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of VSIG4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →